Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D1ONZ8
|
|||
| Drug Name |
AVID200
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-D48; ICD-9: 140-199] | Phase 1 | [1] | |
| Company |
Bristol-Myers Squibb
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Transforming growth factor beta (TGFB) | Target Info | Inhibitor | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03834662) A Trial of AVID200, a Transforming Growth Factor beta (TGFbeta) Inhibitor, in Patients Malignancies. U.S. National Institutes of Health. | |||
| REF 2 | TGF signaling underlies hematopoietic dysfunction and bone marrow failure in Shwachman-Diamond Syndrome. J Clin Invest. 2019 Jun 18;129(9):3821-3826. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.